| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, MO 63110;
Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St. Louis, MO 63104;
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287; and
Division of Medical Virology, University of Cape Town, Cape Town, South Africa
The outbreak of monkeypox in the Unites States in the summer of 2003 was the first occurrence of this smallpox-like disease outside of Africa. This limited human epidemic resulted from cross-infection of prairie dogs by imported African rodents. Although there were no human fatalities, this outbreak illustrates that monkeypox is an emerging natural infection and a potential biological weapon. We characterized a virulence factor expressed by monkeypox (monkeypox inhibitor of complement enzymes or MOPICE). We also compared its structure and regulatory function to homologous complement regulatory proteins of variola (SPICE) and vaccinia (VCP). In multiple expression systems, 5–30% of MOPICE, SPICE, and VCP consisted of function-enhancing disulfide-linked homodimers. Mammalian cells infected with vaccinia virus also expressed VCP dimers. MOPICE bound human C3b/C4b intermediate to that of SPICE and VCP. Cofactor activity of MOPICE was similar to VCP, but both were 
100-fold less efficient than SPICE. SPICE and VCP, but not MOPICE, possessed decay-accelerating activity for the C3 and C5 convertases of the classical pathway. Additionally, all three regulators possessed heparin-binding capability. These studies demonstrate that MOPICE regulates human complement and suggest that dimerization is a prominent feature of these virulence factors. Thus, our data add novel information relative to the functional repertoire of these poxviral virulence factors. Furthermore, targeting and neutralizing these complement regulatory active sites via mAbs is a therapeutic approach that may enhance protection against smallpox.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  M. K. Liszewski, M. K. Leung, R. Hauhart, C. J. Fang, P. Bertram, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Dissecting Functional Sites and Abrogating Activity J. Immunol., September 1, 2009; 183(5): 3150 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R.-E.-I. Benhnia, M. M. McCausland, J. Moyron, J. Laudenslager, S. Granger, S. Rickert, L. Koriazova, R. Kubo, S. Kato, and S. Crotty Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement J. Virol., February 1, 2009; 83(3): 1201 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okroj, L. Mark, A. Stokowska, S. W. Wong, N. Rose, D. J. Blackbourn, B. O. Villoutreix, O. B. Spiller, and A. M. Blom Characterization of the Complement Inhibitory Function of Rhesus Rhadinovirus Complement Control Protein (RCP) J. Biol. Chem., January 2, 2009; 284(1): 505 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Liszewski, P. Bertram, M. K. Leung, R. Hauhart, L. Zhang, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Regulation of Complement Activation on Cells and Mechanism of Its Cellular Attachment J. Immunol., September 15, 2008; 181(6): 4199 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Girgis, B. C. DeHaven, X. Fan, K. M. Viner, M. Shamim, and S. N. Isaacs Cell Surface Expression of the Vaccinia Virus Complement Control Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected Cells from Complement Attack J. Virol., May 1, 2008; 82(9): 4205 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. N. Yadav, K. Pyaram, J. Mullick, and A. Sahu Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement Regulation J. Virol., April 1, 2008; 82(7): 3283 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Parker, W. M. Yokoyama, J. A. Corbett, N. Chen, and R. M. L. Buller Primary naive and interleukin-2-activated natural killer cells do not support efficient ectromelia virus replication J. Gen. Virol., March 1, 2008; 89(3): 751 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beucher and K. A. Norris Sequence Diversity of the Trypanosoma cruzi Complement Regulatory Protein Family Infect. Immun., February 1, 2008; 76(2): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kuttner-Kondo, D. E. Hourcade, V. E. Anderson, N. Muqim, L. Mitchell, D. C. Soares, P. N. Barlow, and M. E. Medof Structure-based Mapping of DAF Active Site Residues That Accelerate the Decay of C3 Convertases J. Biol. Chem., June 22, 2007; 282(25): 18552 - 18562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mark, O. B. Spiller, M. Okroj, S. Chanas, J. A. Aitken, S. W. Wong, B. Damania, A. M. Blom, and D. J. Blackbourn Molecular Characterization of the Rhesus Rhadinovirus (RRV) ORF4 Gene and the RRV Complement Control Protein It Encodes J. Virol., April 15, 2007; 81(8): 4166 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Singh, J. Mullick, J. Bernet, and A. Sahu Functional Characterization of the Complement Control Protein Homolog of Herpesvirus Saimiri: ARG-118 IS CRITICAL FOR FACTOR I COFACTOR ACTIVITIES J. Biol. Chem., August 11, 2006; 281(32): 23119 - 23128. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
